Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Altimmune (NASDAQ:ALT)

Altimmune Expands Weight-Loss Drug Pemvidutide's Potential To Alcohol-Related Disorders - Altimmune (NASDAQ:ALT)

Altimmune Inc (NASDAQ:ALT) hosted a virtual R&D day on Thursday, marking the first disclosure of Alcohol Use Disorder (AUD) and Alcohol Liver Disease (ALD) as potential developments for pemvidutide. Phase 2 trials for pemvidutide in AUD and ALD are expected to start in the second and third quarters of 2025, respectively. Altimmune anticipates pemvidutide will reduce alcohol cravings, improve liver health and promote weight loss. Also Read: Novo …

Altimmune to study obesity drug in alcohol use disorder, following Eli Lilly

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Morning. The Boston biotech scene’s a mess, and Marty Makary’s and Jay Bhattacharya’s nominations have been advanced to the full Senate for FDA and NIH leadership. Also, we see another company testing GLP-1s for alcohol use disorder.Read the rest…

Altimmune to Test Obesity Drug for Alcohol Use Disorder and Related Health Conditions

Altimmune said on Thursday that it plans to test its lead experimental obesity drug, pemvidutide, to potentially treat alcohol use disorder and alcohol-associated liver... Reuters Health Information